Coherus Oncology, Inc.
Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.
What’s moving Coherus Oncology, Inc. now
Current reporting with the operating signal separated from the noise.
Coherus Oncology, Inc.: Coherus and Zumutor Biologics Announce Clinical Collaboration to Evaluate ZM008 in Combination with LOQTORZI (toripalimab-tpzi)
The story matters when it changes Coherus Oncology, Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Coherus Oncology, Inc. Announces Pricing of Public Offering of Common Stock
Investors are testing whether Coherus Oncology, Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Coherus Oncology, Inc. (CHRS) Presents at UBS Virtual Oncology Day Transcript
The story matters when it changes Coherus Oncology, Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Latest CHRS filings.
Investor-relevant reports are shown first, followed by the company’s other recent official submissions.
Coherus Oncology, Inc., quarter by quarter.
Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.
First quarter
No verified period-specific item in the current feed.
SEARCH Q1 COVERAGE →Second quarter
No verified period-specific item in the current feed.
SEARCH Q2 COVERAGE →Third quarter
No verified period-specific item in the current feed.
SEARCH Q3 COVERAGE →Fourth quarter / full year
No verified period-specific item in the current feed.
SEARCH Q4 COVERAGE →